We’ve recently updated our valuation analysis.

Baxter International Valuation

Is BAX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BAX?

Other financial metrics that can be useful for relative valuation.

BAX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA13x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BAX's PS Ratio compare to its peers?

The above table shows the PS ratio for BAX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.5x
HOLX Hologic
4.8x5.3%US$21.2b
STE STERIS
4.5x6.5%US$21.7b
ZBH Zimmer Biomet Holdings
4x3.7%US$27.5b
RMD ResMed
8.8x7.7%US$33.0b
BAX Baxter International
1.6x3.8%US$23.0b


Price to Earnings Ratio vs Industry

How does BAX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a


Price to Sales Ratio vs Fair Ratio

What is BAX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BAX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: BAX is good value based on its Price-To-Sales Ratio (1.6x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).


Share Price vs Fair Value

What is the Fair Price of BAX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BAX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$45.61
US$59.80
+31.1%
14.4%US$85.00US$51.00n/a14
Feb ’24US$46.28
US$60.73
+31.2%
15.2%US$85.00US$51.00n/a14
Jan ’24US$50.97
US$62.83
+23.3%
13.2%US$85.00US$51.00n/a16
Dec ’23US$52.38
US$65.40
+24.9%
11.3%US$85.00US$53.00n/a15
Nov ’23US$53.74
US$65.87
+22.6%
10.4%US$85.00US$58.00n/a15
Oct ’23US$53.86
US$69.92
+29.8%
8.7%US$85.00US$60.00n/a13
Sep ’23US$56.76
US$69.92
+23.2%
8.7%US$85.00US$60.00n/a13
Aug ’23US$58.67
US$70.69
+20.5%
7.6%US$85.00US$63.00n/a13
Jul ’23US$65.49
US$84.92
+29.7%
9.9%US$99.00US$70.00n/a13
Jun ’23US$74.47
US$89.29
+19.9%
8.8%US$105.00US$70.00n/a14
May ’23US$71.06
US$92.47
+30.1%
8.1%US$105.00US$77.00n/a15
Apr ’23US$78.58
US$96.38
+22.6%
5.1%US$105.00US$88.00n/a16
Mar ’23US$84.14
US$96.56
+14.8%
4.8%US$105.00US$90.00n/a16
Feb ’23US$84.93
US$97.14
+14.4%
6.3%US$110.00US$86.00US$46.2814
Jan ’23US$85.84
US$94.08
+9.6%
5.8%US$105.00US$86.00US$50.9713
Dec ’22US$75.08
US$93.08
+24.0%
6.8%US$105.00US$82.00US$52.3813
Nov ’22US$79.82
US$94.00
+17.8%
6.8%US$105.00US$82.00US$53.7415
Oct ’22US$81.29
US$93.93
+15.6%
6.3%US$105.00US$82.00US$53.8615
Sep ’22US$77.60
US$92.12
+18.7%
7.2%US$105.00US$80.00US$56.7617
Aug ’22US$77.35
US$93.00
+20.2%
6.4%US$105.00US$80.00US$58.6717
Jul ’22US$81.47
US$93.59
+14.9%
5.9%US$105.00US$80.00US$65.4917
Jun ’22US$82.14
US$93.59
+13.9%
5.9%US$105.00US$80.00US$74.4717
May ’22US$85.69
US$93.18
+8.7%
6.1%US$105.00US$80.00US$71.0617
Apr ’22US$84.32
US$91.11
+8.1%
8.1%US$105.00US$73.00US$78.5818
Mar ’22US$77.94
US$91.11
+16.9%
8.1%US$105.00US$73.00US$84.1418
Feb ’22US$76.38
US$91.44
+19.7%
8.2%US$105.00US$73.00US$84.9318


Discover undervalued companies